Modality
siRNA
MOA
AHRant
Target
PD-L1
Pathway
RNA Splicing
TTR AmyloidosisEoEBreast Ca
Development Pipeline
Preclinical
~Aug 2015
→ ~Nov 2016
Phase 1
Feb 2017
→ Jul 2029
Phase 1Current
NCT05088440
615 pts·TTR Amyloidosis
2017-02→2029-07·Not yet recruiting
NCT08804021
1,532 pts·TTR Amyloidosis
2017-08→TBD·Not yet recruiting
2,147 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-07-053.3y awayPh2 Data· TTR Amyloidosis
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1/2
Not yet…
P1/2
Not yet…
Catalysts
Ph2 Data
2029-07-05 · 3.3y away
TTR Amyloidosis
Not yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05088440 | Phase 1/2 | TTR Amyloidosis | Not yet recr... | 615 | UPDRS |
| NCT08804021 | Phase 1/2 | TTR Amyloidosis | Not yet recr... | 1532 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| BII-5449 | Biogen | Phase 3 | FXIa | |
| Elratapinarof | Halozyme | Phase 2 | C5 | |
| Nidaratamab | Exelixis | Phase 3 | FLT3 | |
| Polatuximab | Nuvalent | Approved | PD-L1 | |
| VKT-6548 | Viking Therapeutics | Phase 2/3 | PD-L1 | |
| Voxaderotide | Viking Therapeutics | Approved | PD-L1 |